Open Access<p>Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo</p>
Author(s) -
Hongzhang Wu,
Xurui Cheng,
Feiyan Huang,
Gang Shao,
Yueming Meng,
Lingfei Wang,
Tao Wang,
Xiaoyuan Jia,
Tianxin Yang,
Xi Wang,
Caiyun Fu
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s244648
Subject(s) - aprepitant , pharmacology , myeloid leukemia , cytarabine , in vivo , medicine , chemistry , cancer research , chemotherapy , biology , microbiology and biotechnology , antiemetic
Acute myeloid leukemia (AML) is a complex malignancy characterized by the clonal expansion of immature myeloid precursors. The standard treatment for newly diagnosed AML is chemotherapy consisting of cytosine arabinoside (Ara-C) and anthracyclines with disappointing clinical outcomes and severe adverse effects, such as symptomatic bradycardia, neurotoxicity. Thus, it is promising to treat AML through combination drug therapy to reduce the adverse effects of chemotherapeutics. In our recent published PNAS paper, we reported that NK-1R antagonists, both Aprepitant and SR140333, induce apoptosis of myeloid leukemia cells by inducing oxidative stress through mitochondrial calcium overload. We, therefore, tested the hypothesis of the combination Ara-C with NK-1R antagonist could enhance the efficacy of Ara-C.